Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ART6043 Monotherapy and in Combination With Olaparib in Advanced Solid Tumors
NCT05898399Phase 2Recruiting
- Sponsor
- Artios Pharma
- Start
- Jun 2023
- Primary completion
- Jun 2028
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, open-label trial of art6043 in solid tumor and breast cancer (3 arms), sponsored by Artios Pharma. Primary endpoints: Dose Limiting Toxicities at 3 weeks and Progression Free Survival at 3.7 years. Started Jun 2023; status: recruiting.
02
Drugs
art6043
03
Conditions
solid tumorbreast cancer
Beyond the preview
Go deeper on NCT05898399.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05898399.